Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study.

MLA

Narayanan, Sathya, et al. “Therapeutic Drug Monitoring of Osimertinib in EGFR Mutant Non‐small Cell Lung Cancer by Dried Blood Spot and Plasma Collection: A Pilot Study.” British Journal of Clinical Pharmacology, vol. 90, no. 8, Aug. 2024, pp. 1942–51. EBSCOhost, https://doi.org/10.1111/bcp.16070.

APA

Narayanan, S., Yuile, A., Venkatesh, B., McKay, M., Itchins, M., Pavlakis, N., Wheeler, H., Gray, L., Wei, J., Miller, S., Kirwin, B., Molloy, M. P., & Clarke, S. (2024). Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study. British Journal of Clinical Pharmacology, 90(8), 1942–1951. https://doi.org/10.1111/bcp.16070

Chicago

Narayanan, Sathya, Alexander Yuile, Bharat Venkatesh, Matthew McKay, Malinda Itchins, Nick Pavlakis, Helen Wheeler, et al. 2024. “Therapeutic Drug Monitoring of Osimertinib in EGFR Mutant Non‐small Cell Lung Cancer by Dried Blood Spot and Plasma Collection: A Pilot Study.” British Journal of Clinical Pharmacology 90 (8): 1942–51. doi:10.1111/bcp.16070.